An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
17 11 2022
Historique:
received: 17 09 2022
revised: 10 11 2022
accepted: 15 11 2022
entrez: 24 11 2022
pubmed: 25 11 2022
medline: 29 11 2022
Statut: epublish

Résumé

Indoor tanning (sunbeds, solarium) uses artificial ultraviolet radiation (UVR) to stimulate cosmetic tanning of the skin. Indoor tanning has been officially classified as a human carcinogen in 2009 by the International Agency for Research on Cancer of the World Health Organization (WHO). The differences in the prevalence of sunbed use across countries and over the years highlight underlying legislative, climatic, and cultural differences. Indoor tanning-seeking behaviors may be driven by motivations for an appealing appearance, largely influenced by gender and age, and several misconceptions that a prevacation tan safeguards the skin, that sunbeds can be used to treat acne or to increase vitamin D, or that tanning is a healthy habit. This review provides an epidemiological update on the prevalence of sunbed use, who tends to use sunbeds and why, and details the current evidence on the association of sunbeds with skin cancers, including cutaneous melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC). A statistically significant higher risk of cutaneous melanoma, BCC and cSCC with the use of sunbeds has been consistently demonstrated. This risk of skin cancer is even higher with the more frequent use of sunbeds, underscoring a dose-response relationship, and in those first exposed to sunbeds at a younger age. Preventive measures against sunbed use include legislation restricting sunbed use, educational campaigns to inform and discourage from indoor tanning, as well as using the internet, online advertising messages and the social media to reach larger audiences and to promote an untanned appearance.

Identifiants

pubmed: 36421352
pii: curroncol29110699
doi: 10.3390/curroncol29110699
pmc: PMC9689757
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

8886-8903

Références

Hum Mol Genet. 2000 Oct 12;9(17):2531-7
pubmed: 11030758
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:13-27
pubmed: 30811698
Br J Dermatol. 2019 Jun;180(6):1529-1530
pubmed: 30671929
Am J Prev Med. 2013 Jun;44(6):672-81
pubmed: 23683986
Br J Dermatol. 2020 Apr;182(4):849-859
pubmed: 31381131
Int J Cancer. 2007 Mar 1;120(5):1116-22
pubmed: 17131335
Br J Dermatol. 1996 Nov;135(5):712-6
pubmed: 8977669
Photochem Photobiol. 2010 May-Jun;86(3):481-91
pubmed: 20550646
Photodermatol Photoimmunol Photomed. 2022 Jan;38(1):83-85
pubmed: 34157183
J Cutan Med Surg. 2017 Sep/Oct;21(5):401-407
pubmed: 28418712
Acta Derm Venereol. 2019 Sep 1;99(10):878-883
pubmed: 31017252
Dtsch Arztebl Int. 2018 Sep 3;115(35-36):586-593
pubmed: 30236218
J Am Acad Dermatol. 2020 Aug;83(2):511-522
pubmed: 32068044
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):562-6
pubmed: 15767329
J Eur Acad Dermatol Venereol. 2011 May;25(5):610-6; author reply 617-8
pubmed: 21349117
Eur J Cancer. 2001 Dec;37(18):2441-8
pubmed: 11720841
J Health Commun. 2017 Apr;22(4):294-303
pubmed: 28266905
Clin Exp Dermatol. 2022 Feb;47(2):404-406
pubmed: 34407228
Proc R Soc Med. 1965 May;58:295-300
pubmed: 14283879
Am J Epidemiol. 2017 Feb 1;185(3):147-156
pubmed: 28077359
Br J Dermatol. 2018 Dec;179(6):1412-1413
pubmed: 30005129
Scand J Public Health. 2013 Dec;41(8):812-7
pubmed: 23907734
Br J Dermatol. 2020 Nov;183(5):847-856
pubmed: 32030719
Cancers (Basel). 2021 Nov 25;13(23):
pubmed: 34885049
Prev Med. 1997 Jan-Feb;26(1):114-9
pubmed: 9010906
Nature. 2007 Feb 22;445(7130):843-50
pubmed: 17314970
Br J Dermatol. 2011 Jul;165(1):214-6
pubmed: 21457215
Photochem Photobiol. 2011 Sep-Oct;87(5):978-87
pubmed: 21749400
Br J Dermatol. 2022 Jul;187(1):105-114
pubmed: 35141876
Anticancer Res. 2018 Feb;38(2):1187-1199
pubmed: 29374757
Arch Dermatol. 2012 Sep;148(9):1006-12
pubmed: 22801924
JAMA Dermatol. 2015 Dec 01;151(12):1308-1316
pubmed: 26444580
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:57-62
pubmed: 30811691
Br J Dermatol. 2020 Nov;183(5):799-800
pubmed: 32338370
Eur J Cancer. 2005 Sep;41(14):2141-9
pubmed: 16125927
Cancer. 2021 Feb 15;127(4):560-568
pubmed: 33170961
Tob Control. 2011 Sep;20(5):327-37
pubmed: 21606180
JAMA Dermatol. 2019 Dec 1;155(12):1350-1357
pubmed: 31577329
Int J Cancer. 2014 Jul 15;135(2):413-22
pubmed: 24408678
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20
pubmed: 1502162
Int J Environ Res Public Health. 2019 Oct 15;16(20):
pubmed: 31618885
Children (Basel). 2021 May 14;8(5):
pubmed: 34068910
Children (Basel). 2022 May 24;9(6):
pubmed: 35740705
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:6-12
pubmed: 30811690
J Exp Med. 2002 Jan 21;195(2):171-9
pubmed: 11805144
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:89-96
pubmed: 30811694
J Am Acad Dermatol. 2014 May;70(5):847-57.e1-18
pubmed: 24629998
Health Phys. 1999 Oct;77(4):436-40
pubmed: 10492351
JAMA Dermatol. 2018 Sep 1;154(9):1090-1091
pubmed: 30027270
Immunol Today. 1992 Jul;13(7):250-4
pubmed: 1388651
Curr Opin Oncol. 2019 Mar;31(2):65-71
pubmed: 30676536
J Am Acad Dermatol. 2017 Feb;76(2):226-233
pubmed: 27939556
JAMA Dermatol. 2016 Mar;152(3):268-75
pubmed: 26818409
Br J Dermatol. 2019 Oct;181(4):858-859
pubmed: 30972743
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1681-1686
pubmed: 29706005
Sci Rep. 2021 Nov 30;11(1):23180
pubmed: 34848741
Am J Public Health. 2018 Jul;108(7):951-956
pubmed: 29771612
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:97-103
pubmed: 30811700
Am J Ind Med. 2021 Jun;64(6):496-510
pubmed: 33682179
Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):885-892
pubmed: 35064063
Arch Dermatol Res. 2022 Jan;314(1):85-88
pubmed: 32803353
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:104-109
pubmed: 30811688
Am J Prev Med. 2017 Sep;53(3S1):S86-S94
pubmed: 28818251
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:28-33
pubmed: 30811696
Int J Cancer. 2011 May 15;128(10):2425-35
pubmed: 20669232
Int J Cancer. 2012 Aug 1;131(3):706-15
pubmed: 21898390
Br J Dermatol. 2016 Apr;174(4):730-40
pubmed: 26749382
J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1351-5
pubmed: 21711466
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):111-20
pubmed: 20056629
Eur J Cancer Prev. 2013 Mar;22(2):126-30
pubmed: 22895295
Exp Dermatol. 2009 Sep;18(9):741-9
pubmed: 19555431
J Adolesc Health. 2014 Feb;54(2):214-20
pubmed: 24119418
Prev Med. 2009 Mar;48(3):288-90
pubmed: 19154755
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt D):7-303
pubmed: 23189752
BMJ. 2012 Jul 24;345:e4757
pubmed: 22833605
Prev Med. 2019 Jun;123:299-307
pubmed: 30940571
Br J Dermatol. 2022 Jul;187(1):7
pubmed: 35508361
J Clin Oncol. 2012 May 10;30(14):1588-93
pubmed: 22370316
J Am Acad Dermatol. 2015 Jun;72(6):1092-4
pubmed: 25981012
J Eur Acad Dermatol Venereol. 2010 Jun;24(6):639-48
pubmed: 20015180
Br J Dermatol. 2015 Jul;173(1):201-8
pubmed: 25645571
BMJ. 2012 Oct 02;345:e5909
pubmed: 23033409
JAMA Dermatol. 2016 Jan;152(1):101-2
pubmed: 26444220
Br J Dermatol. 2010 Dec;163(6):1269-75
pubmed: 20716213
BMJ. 2020 Feb 4;368:m7
pubmed: 32019742
J Eur Acad Dermatol Venereol. 2015 Jan;29(1):134-42
pubmed: 24684198
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8
pubmed: 27514932
JAMA Dermatol. 2020 Apr 1;156(4):401-410
pubmed: 32074257
JAMA Dermatol. 2014 Apr;150(4):390-400
pubmed: 24477278
J Natl Cancer Inst. 2003 Oct 15;95(20):1530-8
pubmed: 14559875

Auteurs

Clio Dessinioti (C)

Melanoma and Skin Cancer Unit, 1st Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, 16121 Athens, Greece.

Alexander J Stratigos (AJ)

Melanoma and Skin Cancer Unit, 1st Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, 16121 Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH